WO1993021253A1 - Polymers biodegradable or bioerodible into amino acids - Google Patents

Polymers biodegradable or bioerodible into amino acids Download PDF

Info

Publication number
WO1993021253A1
WO1993021253A1 PCT/US1993/003278 US9303278W WO9321253A1 WO 1993021253 A1 WO1993021253 A1 WO 1993021253A1 US 9303278 W US9303278 W US 9303278W WO 9321253 A1 WO9321253 A1 WO 9321253A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
optionally substituted
oxygen
nitrogen
organic radical
Prior art date
Application number
PCT/US1993/003278
Other languages
French (fr)
Inventor
Ronald Swidler
Original Assignee
Sri International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sri International filed Critical Sri International
Publication of WO1993021253A1 publication Critical patent/WO1993021253A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/06At least partially resorbable materials
    • A61L17/10At least partially resorbable materials containing macromolecular materials
    • A61L17/12Homopolymers or copolymers of glycolic acid or lactic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Definitions

  • This invention relates to a class of polyester polymers having ⁇ amino acid repeating units and which will readily hydrolyze under physiological conditions.
  • Such polymer systems are useful for drug delivery, as absorbable sutures, and as dissolvable wound dressings. They can also serve to provide temporary polymeric layers or coatings which hydrolyze and thereby dissipate with time.
  • Such coatings have numerous uses, for example, from temporary protection of metal and other surfaces, to masking during semiconductor processing operations.
  • a number of bioerodible or biodegradable polymers are known and are useful for controlled release of pharmaceuticals. Such polymers are described in, for example, U.S. Patent 4,291,013, issued to H. Wahlig, et al., U.S. Patent 4,347,234, issued to H. Wahlig, et al., U.S. Patent 4,525,495, issued to L.C. Dorman, et al., U.S. Patent 4,570,629, issued to A. idra, U.S. Patent 4,572,832, issued to K. Kigasawa, et al., U.S. Patent 4,587,268, issued to R.W. Pfirrmann, U.S.
  • Patent 4,638,045 issued o J. Kohn, et al., U.S. Patent 4,675,381, issued to D. Bitchon, U.S. Patent 4,745,160, issued to J.R. Churchill, et al., U. S. Patent 4,502,976 to Heller, U.S. Patent 4,080,969, issued to Casey et al., and U.S. Patent 4,888,413, issued to Domb.
  • Kohn, et al. U.S. Patent 4,638,045, which utilizes non-peptide bonds between side chains on dipeptides with the side chains being bonded together by hydrolytically unstable bonds which are biodegradable.
  • the products of hydrolysis of such compounds include the side chains of each monomer unit and are, therefore, not as fully biocompatible as might be desired.
  • the present invention is directed to overcoming one or more of the problems as set forth above.
  • the invention is a biodegradable polyester polymer comprising the structure of Formula I below:
  • R! a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone;
  • R2 a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone;
  • R3 and R 4 are each independently hydrogen or an organic substituent which may be optionally substituted with O, S, or N, or together form a divalent organic ring which may be optionally substituted with O, S, or N; and each R is independently H, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, or cycloalkynyl, all optionally substituted with F, Cl, Br, I, C , or NO 2 .
  • a polymer as set forth above is directly biodegradable into lower molecular weight components of the nature of ⁇ amino acids or substituted amino acids which are highly biocompatible. Biodegradation of the polymer is via hydrolysis of the ester linkage. This can take place readily at pH about 8 or below through the formation of a six membered ring intermediate form.
  • compositions can be incorporated into a matrix made of such a polymer and the matrix can be attached as a patch to the body, used as a pill, used as a lozenge, used as a suppository, or otherwise contacted with the body whereupon on hydrolysis of the polyester linkage the pharmaceutical is released into the body while the only components of the hydrolysis are the ⁇ amino acids which form the polymer chain.
  • the polymers of the invention can also be used to form temporary polymer films which dissolve over a period of time as the polymers are hydrolyzed- Such films can be used, for example, as wound dressings.
  • the polymers can also be used to formulate sutures and such sutures will dissolve away in time.
  • the products of the hydrolysis are usually highly biocompatible.
  • the polymers can also be used as resists or for masking purposes, for example, for semiconductor processing. They can also be used as temporary protective coatings for metals or other materials, particularly when it is desirable to be able to dissolve the coatings away after a period of protection.
  • a biodegradable polyester polymer of Formula I is set forth.
  • the polymer is characterized in that it is a polyester and in that it hydrolyses via a zero order reaction, analogously to the hydrolysis of esters of ⁇ -alanine as reported at Beilstein, 4, 402-
  • the biodegradable polyester polymer hydrolyze into ⁇ amino acids, since in that situation proton catalyzed hydrolysis takes place at pH values of about 8 and below, e.g., at physiological pH, relatively readily via a zero order reaction since a six membered ring can be formed via hydrogen bonding of the protonated (at pH 8 and below) hydrogen of the amino group to the oxygen of the carbonyl group whereby the carbonyl group is readily hydrolyzed by water to form the acid and the corresponding alcohol.
  • the defined values of the subscripts p and q are such that six membered rings are formable.
  • the preferred polymers of the invention can be represented by Formulae II and HI below:
  • n The degree of polymerization, represented by the value of n, is not critical. Usually, n will be chosen such that the molecular weight of the polymer will fall within a range from about 500 to about 5,000. However, the invention is not limited to n values and/or to molecular weights within this range.
  • R and R 2 are each independently a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone. Examples of usable R* and R 2 substituents are set forth below.
  • R3 and R 4 are each independently hydrogen or an organic substituent which may be optionally substituted with O, S, or N, or together form a divalent ring which may be optionally substituted with O, S, or N
  • An example of such a divalent ring is set forth below.
  • Each R can independently be any of H, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, or cycloalkynyl, all optionally substituted with F, Cl, Br, I, CN, or NO 2 .
  • each R can be hydrogen, methyl, or ethyl.
  • the sizes of the R, R , R 2 , R ⁇ and R 4 constituents and their structures and chemical makeup can be chosen so as to provide a desired rate of hydrolysis. If these groups are large, they will lead to relatively slow hydrolysis, since accessibility of the ester linkage being hydrolyzed will be limited by the rate of diffusion of water and hydrogen ion through the polymer.
  • the polymer of the present invention is a biodegradable polyester polymer in structure it may be made by any of a number of procedures.
  • the polymers can be synthesized from polyester polymers having double bonded carbon atoms in the polymer backbone attached to, or one carbon removed from, the carbonyl of the ester linkage.
  • the polyester polymers can themselves be prepared by methods known to the art, for example by reacting an acid or anhydride having a double bond with a polyol, for example a diol. This can be represented with maleic anhydride and substituted maleic anhydrides by the following reaction scheme: O
  • a useful synthesis of the biodegradable or bioerodible polymers of the invention consists of reacting the double bonds in the intermediate polyester polymer (TV) with an amine of the formula NRR ⁇ R4 by the well known Michael reaction.
  • the reaction will often be carried out by mildly heating the reactants, for example, at a temperature of 30 to 150" C. However, dependant upon the particular reactants, chilling to below room temperature may be desirable.
  • the time of reaction can also be varied dependant upon the particular reactants, all in accordance with the vast literature describing the Michael reaction.
  • a polymaleic acid polymer may be formed by reacting maleic anhydride with 1,2-dihydroxyethane at a temperature of above about 100 ⁇ C until sufficient water has been evolved (the water is generally removed by distillation as it is formed) to form the intermediate polyester polymer (IN) which is then reacted with a group ⁇ RR ⁇ R4 as set forth above.
  • the resulting amine containing polyester polymer (EQ) of the invention then has a structure which allows a six membered ring to be formed. If one desires to make the ⁇ type polyester polymer of the formula (H), itaconic acid or the anhydride thereof, or a substituted itaconic acid or anhydride, is substituted for the maleic anhydride.
  • the biodegradable amine substituted polyester polymer (U) or (IH) of the present invention may be made by carrying out the Michael reaction on maleic acid or itaconic acid or the corresponding anhydride or on a derivative thereof to form an N,N dialkyl, etc., derivative followed by esterification (reaction with a diol) to form the desired polymer.
  • Pharmaceuticals or other slow release compounds, for example, pesticides can be incorporated in the polyesterpolymers (J) by including them in solution during the polymerization reaction via which the polymer of the invention or a precursor polymer are formed. The particular pharmaceuticals must naturally not react with the polymer leading to significant loss of activity or to produce undesirable or toxic substances.
  • the polyester polymer can be utilized for purposes other than delivery of pharmaceuticals over a period of time. For example, they can be used to form temporary protective films which biodegrade away in a desirable period of time.
  • Example 1 This Example describes the synthesis of a ⁇ amino acid type polyester polymer of Formula
  • the precipitate was dried in a vacuum oven.
  • the yield of polymer was about 42.36 g (89%).
  • a portion of the polymer, 5 g (21 millimoles), and a molar excess, 5 g (57 millimoles), of mo ⁇ holine, were dissolved in 20 mL of methylethylketone.
  • the solution was heated at 60 ⁇ C for 2 hours. After cooling to room temperature, the solution was added dropwise to 500 mL of methanol.
  • the resulting precipitate was dried in a vacuum oven. NMR of the resulting polymer indicated that no vinyl protons were present and that there was a strong signal corresponding to the structure:
  • Example 3 demonstrates the biodegradability or bioerodibility of the polymer of Example 1.
  • An aliquot of the final polymer product of Example 1 was checked for solubility in aqueous media. When the pH of the aqueous solution was 3.6 or less the polymer readily dissolved.
  • Example 3
  • This Example demonstrates how to produce a ⁇ amino acid type polyester polymer of Formula (H) in accordance with the present invention.
  • a polymaleic acid polymer is formed by reacting substantially equimolar quantities of maleic anhydride and 1,2-dihydroxy ethane to form an intermediate polyester polymer.
  • the intermediate polymer is then reacted with a group NRR3R4.
  • the resulting amine containing polyester polymer has a structure which allows a six membered ring to be formed.
  • protonation leads to hydrolysis (and hence dissolution) at a pH of about 8 or below and the polymer bioerodes and/or biodegrades.
  • the biodegradable polymer in accordance with any of Examples 1-3 has incorporated therein one or more pharmaceuticals and is formulated into a patch which is implanted into a human patient
  • the patch dissolves over a period of time at physiological pH (about 7) and the pharmaceutical is released into the patient during that time.
  • a biodegradable polyester polymer in accordance with any of Examples 1-3 is utilized as a film on a wound for the purpose of protection. After a period of time it has biodegraded and is no longer present
  • a biodegradable polyester polymer in accordance with any of Examples 1-3 is utilized as a resist for semiconductor processing. After use, it is stripped utilizing a solution at pH 8 or below.
  • the present invention provides a biodegradable polyester polymer in which pharmaceuticals can be dispersed and which will biodegrade over a period of time under physiological conditions to release such pharmaceuticals. While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modification, and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as fall within the scope of the invention and the limits of the appended claims.

Abstract

The invention presents a biodegradable polyester polymer having structure (I) wherein: n = number of repeating polymer units of the formula shown; p = 0 or 1, 0 indicating the absence of the subscripted constituent; q = 0 or 1, 0 indicating the absence of the subscripted constituent; when p = 0, q = 1; when p = 1, q = 0; R?1 = a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone; R?2 = a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone; R?3 and R?4 are each independently hydrogen or an organic substituent or together form a divalent ring which may be optionally substituted; and each R is independently H, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, or cycloalkynyl, all optionally substituted with F, Cl, Br, I, CN, or NO2?.

Description

POLYMERS BIODEGRADABLE OR BTOERODTBLE TNTO AMTNO ACTDS
Technical Field
This invention relates to a class of polyester polymers having β amino acid repeating units and which will readily hydrolyze under physiological conditions. Such polymer systems are useful for drug delivery, as absorbable sutures, and as dissolvable wound dressings. They can also serve to provide temporary polymeric layers or coatings which hydrolyze and thereby dissipate with time. Such coatings have numerous uses, for example, from temporary protection of metal and other surfaces, to masking during semiconductor processing operations.
Background of the Invention
A number of bioerodible or biodegradable polymers are known and are useful for controlled release of pharmaceuticals. Such polymers are described in, for example, U.S. Patent 4,291,013, issued to H. Wahlig, et al., U.S. Patent 4,347,234, issued to H. Wahlig, et al., U.S. Patent 4,525,495, issued to L.C. Dorman, et al., U.S. Patent 4,570,629, issued to A. idra, U.S. Patent 4,572,832, issued to K. Kigasawa, et al., U.S. Patent 4,587,268, issued to R.W. Pfirrmann, U.S. Patent 4,638,045, issued o J. Kohn, et al., U.S. Patent 4,675,381, issued to D. Bitchon, U.S. Patent 4,745,160, issued to J.R. Churchill, et al., U. S. Patent 4,502,976 to Heller, U.S. Patent 4,080,969, issued to Casey et al., and U.S. Patent 4,888,413, issued to Domb. Of particular interest is Kohn, et al., U.S. Patent 4,638,045, which utilizes non-peptide bonds between side chains on dipeptides with the side chains being bonded together by hydrolytically unstable bonds which are biodegradable. The products of hydrolysis of such compounds include the side chains of each monomer unit and are, therefore, not as fully biocompatible as might be desired.
The present invention is directed to overcoming one or more of the problems as set forth above.
Disclosure Of Invention
The invention is a biodegradable polyester polymer comprising the structure of Formula I below:
-(Rl- CR-(CR2)pCO2-R2)n- I (CR2)q Φ
I CR2NR3R4 wherein: n = number of repeating polymer units of -the formula shown; p = 0 or 1, 0 indicating the absence of the subscripted constituent; q = 0 or 1, 0 indicating the absence of the subscripted constituent; whenp =0, q = l; when p = 1, q = 0;
R! = a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone;
R2 = a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone;
R3 and R4 are each independently hydrogen or an organic substituent which may be optionally substituted with O, S, or N, or together form a divalent organic ring which may be optionally substituted with O, S, or N; and each R is independently H, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, or cycloalkynyl, all optionally substituted with F, Cl, Br, I, C , or NO2.
A polymer as set forth above is directly biodegradable into lower molecular weight components of the nature of β amino acids or substituted amino acids which are highly biocompatible. Biodegradation of the polymer is via hydrolysis of the ester linkage. This can take place readily at pH about 8 or below through the formation of a six membered ring intermediate form.
Pharmaceuticals can be incorporated into a matrix made of such a polymer and the matrix can be attached as a patch to the body, used as a pill, used as a lozenge, used as a suppository, or otherwise contacted with the body whereupon on hydrolysis of the polyester linkage the pharmaceutical is released into the body while the only components of the hydrolysis are the β amino acids which form the polymer chain. The polymers of the invention can also be used to form temporary polymer films which dissolve over a period of time as the polymers are hydrolyzed- Such films can be used, for example, as wound dressings. The polymers can also be used to formulate sutures and such sutures will dissolve away in time. The products of the hydrolysis are usually highly biocompatible. The polymers can also be used as resists or for masking purposes, for example, for semiconductor processing. They can also be used as temporary protective coatings for metals or other materials, particularly when it is desirable to be able to dissolve the coatings away after a period of protection.
In accordance with the present invention, a biodegradable polyester polymer of Formula I is set forth. The polymer is characterized in that it is a polyester and in that it hydrolyses via a zero order reaction, analogously to the hydrolysis of esters of β-alanine as reported at Beilstein, 4, 402-
3, to form β amino acids. It is essential that the biodegradable polyester polymer hydrolyze into β amino acids, since in that situation proton catalyzed hydrolysis takes place at pH values of about 8 and below, e.g., at physiological pH, relatively readily via a zero order reaction since a six membered ring can be formed via hydrogen bonding of the protonated (at pH 8 and below) hydrogen of the amino group to the oxygen of the carbonyl group whereby the carbonyl group is readily hydrolyzed by water to form the acid and the corresponding alcohol. The defined values of the subscripts p and q are such that six membered rings are formable. Thus, the preferred polymers of the invention can be represented by Formulae II and HI below:
-(R1- CR-CO2-R2)n-
I dD
CR NR3R4 and
-(Rl- CR-CR2-CO-O-R2)n- I on)
NR3R4
The degree of polymerization, represented by the value of n, is not critical. Usually, n will be chosen such that the molecular weight of the polymer will fall within a range from about 500 to about 5,000. However, the invention is not limited to n values and/or to molecular weights within this range. R and R2 are each independently a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone. Examples of usable R* and R2 substituents are set forth below.
R3 and R4 are each independently hydrogen or an organic substituent which may be optionally substituted with O, S, or N, or together form a divalent ring which may be optionally substituted with O, S, or N An example of such a divalent ring is set forth below.
Each R can independently be any of H, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, or cycloalkynyl, all optionally substituted with F, Cl, Br, I, CN, or NO2. For very ready hydrolysis, each R can be hydrogen, methyl, or ethyl. The sizes of the R, R , R2, R^ and R4 constituents and their structures and chemical makeup can be chosen so as to provide a desired rate of hydrolysis. If these groups are large, they will lead to relatively slow hydrolysis, since accessibility of the ester linkage being hydrolyzed will be limited by the rate of diffusion of water and hydrogen ion through the polymer. Conversely, if the groups are small the hydrolysis rate will generally be large. While the polymer of the present invention is a biodegradable polyester polymer in structure it may be made by any of a number of procedures. The polymers can be synthesized from polyester polymers having double bonded carbon atoms in the polymer backbone attached to, or one carbon removed from, the carbonyl of the ester linkage. The polyester polymers can themselves be prepared by methods known to the art, for example by reacting an acid or anhydride having a double bond with a polyol, for example a diol. This can be represented with maleic anhydride and substituted maleic anhydrides by the following reaction scheme: O
O=C C=O + HOCR2CR2OH
RC=CR
i
-(CO-CR=CR-CO-O-CR2-CR -O)n- (TV).
An additional CR2 group can be present between one of the C=O groups and the adjacent =CR group, taking into account the requirement that a six membered ring be formable to promote hydrolysis.
A useful synthesis of the biodegradable or bioerodible polymers of the invention consists of reacting the double bonds in the intermediate polyester polymer (TV) with an amine of the formula NRR^R4 by the well known Michael reaction. The reaction will often be carried out by mildly heating the reactants, for example, at a temperature of 30 to 150" C. However, dependant upon the particular reactants, chilling to below room temperature may be desirable. The time of reaction can also be varied dependant upon the particular reactants, all in accordance with the vast literature describing the Michael reaction.
For example, a polymaleic acid polymer may be formed by reacting maleic anhydride with 1,2-dihydroxyethane at a temperature of above about 100βC until sufficient water has been evolved (the water is generally removed by distillation as it is formed) to form the intermediate polyester polymer (IN) which is then reacted with a group ΝRR^R4 as set forth above. The resulting amine containing polyester polymer (EQ) of the invention then has a structure which allows a six membered ring to be formed. If one desires to make the β type polyester polymer of the formula (H), itaconic acid or the anhydride thereof, or a substituted itaconic acid or anhydride, is substituted for the maleic anhydride. Alternatively, the biodegradable amine substituted polyester polymer (U) or (IH) of the present invention may be made by carrying out the Michael reaction on maleic acid or itaconic acid or the corresponding anhydride or on a derivative thereof to form an N,N dialkyl, etc., derivative followed by esterification (reaction with a diol) to form the desired polymer. Pharmaceuticals or other slow release compounds, for example, pesticides, can be incorporated in the polyesterpolymers (J) by including them in solution during the polymerization reaction via which the polymer of the invention or a precursor polymer are formed. The particular pharmaceuticals must naturally not react with the polymer leading to significant loss of activity or to produce undesirable or toxic substances. It should be noted that some of the substituents suggested as possible for the groups R, R1, R2, R3 and R4 are such as might make the degradation products not as biocompatible as might be desirable. However, when such substituents are present, the polyester polymer can be utilized for purposes other than delivery of pharmaceuticals over a period of time. For example, they can be used to form temporary protective films which biodegrade away in a desirable period of time.
The invention will be better understood by reference to the following illustrative examples.
Example 1 This Example describes the synthesis of a γ amino acid type polyester polymer of Formula
(I) in accordance with the present invention.
To a 250 mL round bottom flask were charged about 26.02 g (200 millimoles) of itaconic acid, 28.84 g (200 millimoles) of trans-cyclohexanedimethanol, 100 mL of toluene, 100 mg of p- toluene sulfonic acid, and 100 mg of Antioxidant 330 (a trademark of Ethyl Corporation). The flask was equipped with a magnetic stirring bar, a distillation condenser, and a Dean-Stark receiver. The reaction flask was heated at 150°C until 7.2 mL of water were collected in the receiver. The solution was cooled at room temperature and was added dropwise to 500 mL of methanol with vigorous stirring. The precipitate was dried in a vacuum oven. The yield of polymer was about 42.36 g (89%). A portion of the polymer, 5 g (21 millimoles), and a molar excess, 5 g (57 millimoles), of moφholine, were dissolved in 20 mL of methylethylketone. The solution was heated at 60βC for 2 hours. After cooling to room temperature, the solution was added dropwise to 500 mL of methanol. The resulting precipitate was dried in a vacuum oven. NMR of the resulting polymer indicated that no vinyl protons were present and that there was a strong signal corresponding to the structure:
CH2CH2
NCH2C5H2
Example 2
This Example demonstrates the biodegradability or bioerodibility of the polymer of Example 1. An aliquot of the final polymer product of Example 1 was checked for solubility in aqueous media. When the pH of the aqueous solution was 3.6 or less the polymer readily dissolved. Example 3
This Example demonstrates how to produce a β amino acid type polyester polymer of Formula (H) in accordance with the present invention.
A polymaleic acid polymer is formed by reacting substantially equimolar quantities of maleic anhydride and 1,2-dihydroxy ethane to form an intermediate polyester polymer. The intermediate polymer is then reacted with a group NRR3R4. The resulting amine containing polyester polymer has a structure which allows a six membered ring to be formed. As a result, protonation leads to hydrolysis (and hence dissolution) at a pH of about 8 or below and the polymer bioerodes and/or biodegrades.
Example 4
The biodegradable polymer in accordance with any of Examples 1-3 has incorporated therein one or more pharmaceuticals and is formulated into a patch which is implanted into a human patient The patch dissolves over a period of time at physiological pH (about 7) and the pharmaceutical is released into the patient during that time.
Exam le 5
A biodegradable polyester polymer in accordance with any of Examples 1-3 is utilized as a film on a wound for the purpose of protection. After a period of time it has biodegraded and is no longer present
Example 6
A biodegradable polyester polymer in accordance with any of Examples 1-3 is utilized as a resist for semiconductor processing. After use, it is stripped utilizing a solution at pH 8 or below.
Industrial Applicability
The present invention provides a biodegradable polyester polymer in which pharmaceuticals can be dispersed and which will biodegrade over a period of time under physiological conditions to release such pharmaceuticals. While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modification, and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as fall within the scope of the invention and the limits of the appended claims.

Claims

5 WHAT TS CLAIMED TS:'
1. A biodegradable polyester polymer, comprising the formula:
-(Rl- CR-(CR2)pCO2-R2)n-
10 I
(CR2)q
CR2NR3R4
15 wherein:
n = number of repeating polymer units of the formula; p = 0 or 1, 0 indicating the absence of the subscripted constituent; q = 0 or 1, 0 indicating the absence of the subscripted constituent; 20 when p = 0, q = l; when p = 1, q = 0;
Rl = a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone;
R2 = a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur 25 atoms as part of the polymer backbone;
R3 and R4 are each independently hydrogen or an organic substituent which may be optionally substituted with O, S, or N or together form a divalent ring which may be optionally substituted with O, S, or N; and each R is independently H, alkyl, alkenyl or alkynyl, aryl, aralkyl, cycloalkyl, 30 cycloalkenyl or cycloalkynyl, all optionally substituted with F, Cl, Br, I, CN, or NO2.
2. The polymer of Claim 1, wherein each R = H, methyl, or ethyl.
3. A biodegradable polyester polymer, comprising the formulae:
-(Rl- CR-CO2-R2)r
I CR2NR3R4
or
-(Rl- CR-CR2-CO-O-R2)n-
I NR3R4
wherein:
n = number of repeating polymer units of the formulae;
Rl = a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone;
R2 = a divalent organic radical optionally substituted with oxygen, nitrogen, or sulfur atoms as part of the polymer backbone; R3 and R4 are each independently hydrogen or an organic substituent which may be optionally substituted with O, S, or N or together form a divalent ring which may be optionally substituted with O, S σrN; and each R is independently H, alkyl, alkenyl or alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, or cycloalkynyl, all optionally substituted with F, Cl, Br, I, CN, or NO2.
The polymer of Claim 3, wherein each R = H, methyl, or ethyl.
PCT/US1993/003278 1992-04-16 1993-04-08 Polymers biodegradable or bioerodible into amino acids WO1993021253A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/870,447 US5219980A (en) 1992-04-16 1992-04-16 Polymers biodegradable or bioerodiable into amino acids
US07/870,447 1992-04-16

Publications (1)

Publication Number Publication Date
WO1993021253A1 true WO1993021253A1 (en) 1993-10-28

Family

ID=25355393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/003278 WO1993021253A1 (en) 1992-04-16 1993-04-08 Polymers biodegradable or bioerodible into amino acids

Country Status (2)

Country Link
US (1) US5219980A (en)
WO (1) WO1993021253A1 (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767168A (en) 1995-03-30 1998-06-16 The Proctor & Gamble Company Biodegradable and/or compostable polymers made from conjugated dienes such as isoprene and 2,3-dimethyl-1, 3-butadiene
US5759569A (en) * 1995-01-10 1998-06-02 The Procter & Gamble Company Biodegradable articles made from certain trans-polymers and blends thereof with other biodegradable components
US5610241A (en) * 1996-05-07 1997-03-11 Cornell Research Foundation, Inc. Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers
US6517869B1 (en) 1997-12-12 2003-02-11 Expression Genetics, Inc. Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US7807210B1 (en) 2000-10-31 2010-10-05 Advanced Cardiovascular Systems, Inc. Hemocompatible polymers on hydrophobic porous polymers
US6780424B2 (en) * 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6695920B1 (en) 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US6967234B2 (en) * 2002-12-18 2005-11-22 Ethicon, Inc. Alkyd-lactone copolymers for medical applications
US7030127B2 (en) * 2001-06-29 2006-04-18 Ethicon, Inc. Composition and medical devices utilizing bioabsorbable polymeric waxes
US7034037B2 (en) 2001-06-29 2006-04-25 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
US7682669B1 (en) 2001-07-30 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device
US8303651B1 (en) 2001-09-07 2012-11-06 Advanced Cardiovascular Systems, Inc. Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
US7005136B2 (en) 2002-03-29 2006-02-28 Ethicon, Inc. Bone replacement materials utilizing bioabsorbable liquid polymers
US7326426B2 (en) * 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US7368125B2 (en) * 2002-06-05 2008-05-06 Ethicon, Inc. Amphiphilic polymers for medical applications
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US7026374B2 (en) * 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
US7101566B2 (en) * 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
KR20120104412A (en) 2002-09-06 2012-09-20 인설트 테라페틱스, 인코퍼레이티드 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
US6896965B1 (en) 2002-11-12 2005-05-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices
US7758880B2 (en) 2002-12-11 2010-07-20 Advanced Cardiovascular Systems, Inc. Biocompatible polyacrylate compositions for medical applications
US7776926B1 (en) 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
US7074276B1 (en) 2002-12-12 2006-07-11 Advanced Cardiovascular Systems, Inc. Clamp mandrel fixture and a method of using the same to minimize coating defects
US8435550B2 (en) 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7758881B2 (en) 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US20060002968A1 (en) 2004-06-30 2006-01-05 Gordon Stewart Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US6872799B2 (en) * 2002-12-18 2005-03-29 Ethicon, Inc. Functionalized polymers for medical applications
US6866860B2 (en) 2002-12-19 2005-03-15 Ethicon, Inc. Cationic alkyd polyesters for medical applications
US20040120981A1 (en) * 2002-12-20 2004-06-24 Aruna Nathan Crosslinked alkyd polyesters for medical applications
US7063884B2 (en) 2003-02-26 2006-06-20 Advanced Cardiovascular Systems, Inc. Stent coating
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7785512B1 (en) 2003-07-31 2010-08-31 Advanced Cardiovascular Systems, Inc. Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US8192752B2 (en) 2003-11-21 2012-06-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US7220816B2 (en) 2003-12-16 2007-05-22 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US7435788B2 (en) 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US8685431B2 (en) 2004-03-16 2014-04-01 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US7820732B2 (en) 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US7563780B1 (en) 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
US20050287184A1 (en) 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
US8357391B2 (en) 2004-07-30 2013-01-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US7494665B1 (en) 2004-07-30 2009-02-24 Advanced Cardiovascular Systems, Inc. Polymers containing siloxane monomers
US7311980B1 (en) 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
US7648727B2 (en) 2004-08-26 2010-01-19 Advanced Cardiovascular Systems, Inc. Methods for manufacturing a coated stent-balloon assembly
US7244443B2 (en) 2004-08-31 2007-07-17 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrophilic monomers
US8110211B2 (en) 2004-09-22 2012-02-07 Advanced Cardiovascular Systems, Inc. Medicated coatings for implantable medical devices including polyacrylates
US7166680B2 (en) 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
US8603634B2 (en) 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US7390497B2 (en) 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US7481835B1 (en) 2004-10-29 2009-01-27 Advanced Cardiovascular Systems, Inc. Encapsulated covered stent
US7214759B2 (en) 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
US8609123B2 (en) 2004-11-29 2013-12-17 Advanced Cardiovascular Systems, Inc. Derivatized poly(ester amide) as a biobeneficial coating
US7892592B1 (en) 2004-11-30 2011-02-22 Advanced Cardiovascular Systems, Inc. Coating abluminal surfaces of stents and other implantable medical devices
US7604818B2 (en) 2004-12-22 2009-10-20 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrocarbon monomers
US7419504B2 (en) 2004-12-27 2008-09-02 Advanced Cardiovascular Systems, Inc. Poly(ester amide) block copolymers
US8007775B2 (en) 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US7202325B2 (en) 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
US7795467B1 (en) 2005-04-26 2010-09-14 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial polyurethanes for use in medical devices
US8778375B2 (en) 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
US7637941B1 (en) 2005-05-11 2009-12-29 Advanced Cardiovascular Systems, Inc. Endothelial cell binding coatings for rapid encapsulation of bioerodable stents
US7823533B2 (en) 2005-06-30 2010-11-02 Advanced Cardiovascular Systems, Inc. Stent fixture and method for reducing coating defects
US8021676B2 (en) 2005-07-08 2011-09-20 Advanced Cardiovascular Systems, Inc. Functionalized chemically inert polymers for coatings
US7785647B2 (en) 2005-07-25 2010-08-31 Advanced Cardiovascular Systems, Inc. Methods of providing antioxidants to a drug containing product
US7735449B1 (en) 2005-07-28 2010-06-15 Advanced Cardiovascular Systems, Inc. Stent fixture having rounded support structures and method for use thereof
US7976891B1 (en) 2005-12-16 2011-07-12 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method of using focused acoustic energy
US7591841B2 (en) 2005-12-16 2009-09-22 Advanced Cardiovascular Systems, Inc. Implantable devices for accelerated healing
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
US7638156B1 (en) 2005-12-19 2009-12-29 Advanced Cardiovascular Systems, Inc. Apparatus and method for selectively coating a medical article
US20070196428A1 (en) 2006-02-17 2007-08-23 Thierry Glauser Nitric oxide generating medical devices
US7601383B2 (en) 2006-02-28 2009-10-13 Advanced Cardiovascular Systems, Inc. Coating construct containing poly (vinyl alcohol)
US7713637B2 (en) 2006-03-03 2010-05-11 Advanced Cardiovascular Systems, Inc. Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
US7985441B1 (en) 2006-05-04 2011-07-26 Yiwen Tang Purification of polymers for coating applications
US8069814B2 (en) 2006-05-04 2011-12-06 Advanced Cardiovascular Systems, Inc. Stent support devices
US8304012B2 (en) 2006-05-04 2012-11-06 Advanced Cardiovascular Systems, Inc. Method for drying a stent
US7775178B2 (en) 2006-05-26 2010-08-17 Advanced Cardiovascular Systems, Inc. Stent coating apparatus and method
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US8568764B2 (en) 2006-05-31 2013-10-29 Advanced Cardiovascular Systems, Inc. Methods of forming coating layers for medical devices utilizing flash vaporization
US8703167B2 (en) 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US8778376B2 (en) 2006-06-09 2014-07-15 Advanced Cardiovascular Systems, Inc. Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8114150B2 (en) 2006-06-14 2012-02-14 Advanced Cardiovascular Systems, Inc. RGD peptide attached to bioabsorbable stents
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US8703169B1 (en) 2006-08-15 2014-04-22 Abbott Cardiovascular Systems Inc. Implantable device having a coating comprising carrageenan and a biostable polymer
US8597673B2 (en) 2006-12-13 2013-12-03 Advanced Cardiovascular Systems, Inc. Coating of fast absorption or dissolution
JP2010516625A (en) 2007-01-24 2010-05-20 インサート セラピューティクス, インコーポレイテッド Polymer-drug conjugates with tether groups for controlled drug delivery
US8147769B1 (en) 2007-05-16 2012-04-03 Abbott Cardiovascular Systems Inc. Stent and delivery system with reduced chemical degradation
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US8109904B1 (en) 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices
CN102781237A (en) * 2009-11-23 2012-11-14 天蓝制药公司 Cyclodextrin-based polymers for therapeutic delivery
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205997A1 (en) * 1973-11-21 1976-06-23 American Cyanamid Co NORMALLY SOLID BIODEGRADABLE AND HYDROLYZABLE POLYESTER RESIN
DE2843963A1 (en) * 1978-10-09 1980-04-24 Merck Patent Gmbh BODY-RESORBABLE SHAPED MATERIAL BASED ON COLLAGEN AND THEIR USE IN MEDICINE
US4570629A (en) * 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
US4502976A (en) * 1982-10-25 1985-03-05 Bend Research, Inc. Water soluble polyesters
US4525495A (en) * 1983-07-22 1985-06-25 The Dow Chemical Company Mineral filled composites
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4888413A (en) * 1988-01-11 1989-12-19 Domb Abraham J Poly(propylene glycol fumarate) compositions for biomedical applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent Publications Ltd., London, GB; AN 74-49686V (27) *

Also Published As

Publication number Publication date
US5219980A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
US5219980A (en) Polymers biodegradable or bioerodiable into amino acids
US4999417A (en) Biodegradable polymer compositions
US5962520A (en) Hydrolytically unstable, biocompatible polymer
AU750424B2 (en) Polyanhydrides with therapeutically useful degradation products
JP2700646B2 (en) Polymeric polyanhydride
KR101726715B1 (en) Biodegradable polymer-bioactive moiety conjugates
EP0656026B1 (en) Polyarylates containing derivatives of the natural amino acid l-tyrosine
AU729552B2 (en) Monomers derived from hydroxy acids and polymers prepared therefrom
US20200262974A1 (en) Sustained release composition using biobased biodegradable hyperbranched polyesters
Vert Chemical routes to poly (β-malic acid) and potential applications of this water-soluble bioresorbable poly (β-hydroxy alkanoate)
de Gracia Lux et al. Intramolecular cyclization assistance for fast degradation of ornithine‐based poly (ester amide) s
CA2387558A1 (en) Polyanhydrides with biologically active degradation products
JP2002504939A (en) Biodegradable polyester urethane, production method thereof and use thereof
US9144579B2 (en) Polyesters and methods of use thereof
Kricheldorf et al. Resorbable initiators for polymerizations of lactones
US5463012A (en) Polycarbonates and the use thereof for the preparation of bioerosible matrices
EP0726920A1 (en) High molecular weight polyesterpolycarbonates and the use thereof for the preparation of bioerosible matrices
JP5081615B2 (en) Use of catalyst system for (co) oligopolymerization of lactide and glycolide
US5473103A (en) Biopolymers derived from hydrolyzable diacid fats
Bueno Martínez et al. Hydrolytic degradation of poly (ester amides) derived from carbohydrates
Al-Azemi et al. Synthesis of novel bis-and tris-(cyclic carbonate) s and their use in preparation of polymer networks
KR20090059880A (en) Preparation of copolymer containing polyesters segment via ring-opening polymerization of cyclic ester monomer in the presence of activated agent
US4320753A (en) Malic acid polymers
CN101037500B (en) Usage of amidocyanogen containing small molecule compound and method for preparing biodegradable materials
Couffin‐Hoarau et al. Enlarging the library of poly‐(l‐lysine citramide) polyelectrolytic drug carriers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA